摘要
结核病是目前世界上仅次于艾滋病的第二大致死感染性疾病。近10年来,抗结核药物开发已取得很多实质性进展。其中硝基咪唑类化合物很有希望成为新型抗结核化疗药物,防治结核病。这类化合物可有效地缩短了治疗时间,并对耐药性结核分枝杆菌菌株有效。在目前研究开发的硝基咪唑类化合物中,PA-824、OPC-67683目前已进入抗结核病的临床2期实验,这对具有抗结核活性的硝基咪唑类化合物的未来发展方向有着重要意义。本文综述了这些具有抗结核活性的硝基咪唑类化合物的研究历程和目前的发展状况。
Tuberculosis（TB） is the leading cause of death as an infectious disease worldwide,second to the acquired immunodeficiency syndrome.TB drug development has been substantially progressed in the past decade.A series of compound of nitroimidazoles are promising novel drugs as effective chemotherapies to combat TB,which can effectively shorten the duration of treatment and are active against drug-resistant Mycobaeterium tuberculosis strains.Among them,PA-824 and OPC-67683 are currently in Phase Ⅱ clinical trials for the treatment of TB and their outcome may determine the future directions of drug development for anti-tubercular nitroimidazoles.The development of these nitroimidazoles is summarized in this review.
出处
《药学与临床研究》
2013年第5期551-556,共6页
Pharmaceutical and Clinical Research
